The economic burden and quality of life of patients with psoriasis treated with biologics in China

References

• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and ­prevalence. J Invest Dermatol. 2013;133(2):1–6. doi: 10.1038/jid.2012.339.
   Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590.
   PubMed Web of Science ®Google Scholar
• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516. doi: 10.1016/j.jaad.2013.11.013.
   PubMed Web of Science ®Google Scholar
• Springate DA, Parisi R, Kontopantelis E, et al. Incidence, prevalence and mortality of patients with psoriasis: a UK population-based cohort study. Br J Dermatol. 2017;176(3):650–658. doi: 10.1111/bjd.15021.
   PubMed Web of Science ®Google Scholar
• Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663–667. doi: 10.1684/ejd.2012.1802.
   PubMed Web of Science ®Google Scholar
• Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol. 2008;26(5):424–431. doi: 10.1016/j.clindermatol.2007.10.024.
   PubMed Web of Science ®Google Scholar
• Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–991. doi: 10.1038/jid.2014.530.
   PubMed Web of Science ®Google Scholar
• Lesner K, Reich A, Szepietowski JC, et al. Determinants of psychosocial health in psoriatic patients: a multi-national study. Acta Derm Venereol. 2017;97(10):1182–1188. doi: 10.2340/00015555-2760.
   PubMed Web of Science ®Google Scholar
• Vañó-Galván S, Gárate MT, Fleta-Asín B[, et al. Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis. Actas Dermosifiliogr. 2012;103(2):127–137. doi: 10.1016/j.ad.2011.05.002.
   PubMedGoogle Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871–881.e1-30. doi: 10.1016/j.jaad.2013.12.018.
   PubMed Web of Science ®Google Scholar
• Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432–1440. doi: 10.1111/j.1365-4632.2011.05359.x.
   PubMed Web of Science ®Google Scholar
• Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007;57(6):963–971. doi: 10.1016/j.jaad.2007.07.023.
   PubMed Web of Science ®Google Scholar
• Berger K, Ehlken B, Kugland B, et al. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3(7):511–518. doi: 10.1111/j.1610-0387.2005.05729.x.
   PubMedGoogle Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: 10.1016/j.jaad.2018.11.057.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. doi: 10.1016/S0140-6736(15)60125-8.
   PubMed Web of Science ®Google Scholar
• Balogh O, Brodszky V, Gulácsi L, et al. Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur J Health Econ. 2014;15(Suppl 1): s101–s109. doi: 10.1007/s10198-014-0599-z.
   PubMedGoogle Scholar
• Ghatnekar O, Ljungberg A, Wirestrand LE, et al. Costs and quality of life for psoriatic patients at different degrees of severity in Southern Sweden – a cross-sectional study. Eur J Dermatol. 2012;22(2):238–245. doi: 10.1684/ejd.2011.1635.
   PubMed Web of Science ®Google Scholar
• Zhao MY, Wu J, Li YM. Economic burden of patients with moderate to severe psoriasis and its influencing factors (in Chinese). Chin J Dermatol. 2014;47:817–820.
   Google Scholar
• Chen XL, Zheng LY, Zhang H, et al. Disease burden and quality of life in patients with psoriasis: an internet-based questionnaire survey (in Chinese). Chin J Dermatol. 2019;52(11):791–795.
   Google Scholar
• Shiba M, Kato T, Izumi T, et al. Risk of myocardial infarction in patients with psoriasis: a cross-sectional patient-population study in a Japanese hospital. J Cardiol. 2019;73(4):276–279. doi: 10.1016/j.jjcc.2018.10.008.
   PubMed Web of Science ®Google Scholar
• Furue M, Tsuji G, Chiba T, et al. Cardiovascular and metabolic diseases comorbid with psoriasis: beyond the skin. Intern Med. 2017;56(13):1613–1619. doi: 10.2169/internalmedicine.56.8209.
   PubMed Web of Science ®Google Scholar
• Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol. 2018;9:1668. (doi: 10.3389/fimmu.2018.01668.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–1250. doi: 10.1001/archdermatol.2012.2502.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Guérin A, Sundaram M, et al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81–90. doi: 10.1016/j.jaad.2016.07.042.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Iinuma S, Tsuji H, et al. Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients. J Dermatol. 2014;41(8):686–689. doi: 10.1111/1346-8138.12544.
   PubMed Web of Science ®Google Scholar
• Norris D, Photiou L, Tacey M, et al. Biologics and dermatology life quality index (DLQI) in the australasian psoriasis population. J Dermatolog Treat. 2017;28(8):731–736. doi: 10.1080/09546634.2017.1329501.
   PubMed Web of Science ®Google Scholar